| Name | Title | Contact Details |
|---|
Kelcourt Plastics Inc is a San Clemente, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Body Vision Medical is an early commercial stage medical device company specialising in augmented real-time imaging, artificial intelligence and intra-body navigation.
MediChair/Medi-E-Ox is a Goderich, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
We focus on improving the lives of our patients with collaborative care, breakthrough research and by training tomorrow`s physicians. We are University of Minnesota Physicians, the multi-specialty group practice for the University of Minnesota Medical School faculty. As clinicians, we practice in primary care and over 100 specialty and subspecialty areas. As educators, we apply our state-of-the-art knowledge to teach and mentor future physicians. As researchers, we address critical medical problems, then translate our research findings into novel therapies to benefit patients. Our physicians practice academic medicine in an environment of inquiry and education. They work closely with other specialists across disciplines so that our patients receive comprehensive, well-coordinated care tied directly to innovations developed by our research. At UMPhysicians, every employee and physician has a role to play in fostering a culture of integrity and demonstrating our values of Service, Innovation and Respect.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.